Pfizer (PFE) is on track to generate strong revenue and operating cash flow in 2021, with a large contribution from its Covid-19 vaccine, says David Toung, Senior Analyst of Medical Devices and Healthcare Services at Argus Research. He, and Sel Hardy, Equity Analyst at CFRA Research discuss the outlook for health care stocks. CFRA has a strong buy rating on Pfizer with a $57 price target and a buy rating on Johnson & Johnson (JNJ) with a $189 price target. Tune in to find out more.